IP Library Granted Patent US 7,345,085
Granted Patent B2
US 7,345,085 · App. 11/714,341 · Granted Mar 18, 2008

Indoles having anti-diabetic activity

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,345,085
App. No.
11/714,341
Granted
Mar 18, 2008
Kind
B2
Abstract

Indoles having aryloxyalkanoic acid substituents or arylalkanoic acid substituents are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.

Claims (26)

1. A method of treating a disease, condition or disorder selected from the group consisting of (1) non-insulin dependent Type 2 diabetes mellitus (NIDDM), (2) hyperglycemia, (3) low glucose tolerance, (4) insulin resistance, (6) a lipid disorder, (7) dyslipidemia, (8) hyperlipidemia, (9) hypertriglyceridemia, (10) hypercholesterolemia, (11) low HDL levels, (12) high LDL levels, (13) atherosclerosis, comprising administering an effective amount of a compound selected from the group consisting of:

or a pharmaceutically acceptable salt or solvate thereof.

2. A method in accordance with claim 1 further comprising administering to a patient in need of such treatment a therapeutically effective amount of an HMG-CoA reductase inhibitor.

3. The method of claim 2 , wherein the HMG-CoA reductase inhibitor is a statin selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, itavastatin, ZD-4522, rivastatin, and rosuvastatin.

4. A method in accordance with claim 1 wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

5. A method in accordance with claim 1 wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

6. A method in accordance with claim 1 wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

7. A method in accordance with claim 1 wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

8. A method in accordance with claim 1 wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.

10. A phannaceutical composition in accordance with claim 9 wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition in accordance with claim 9 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition in accordance with claim 9 wherein the compound is of the formula;

or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition in accordance with claim 9 wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition in accordance with claim 9 wherein the compound is of the formula

or a pharmaceutically acceptable salt thereof.

Assignments (4)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
CHANGE OF NAME Recorded Aug 29, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028866/0511 →
MERGER Recorded Aug 27, 2012
From: MERCK SHARP & DOHME CORP.
To: SCHERING CORPORATION
Reel/Frame 028850/0515 →
CHANGE OF NAME Recorded Jan 29, 2010
From: MERCK & CO., INC.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 023861/0910 →